AZTR
Price
$0.07
Change
-$0.05 (-41.67%)
Updated
Oct 13 closing price
Capitalization
4.33M
20 days until earnings call
Intraday BUY SELL Signals
GUTS
Price
$1.15
Change
-$0.01 (-0.87%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
183.06M
20 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AZTR vs GUTS

AZTR vs GUTS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AZTR vs. GUTS commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZTR is a Hold and GUTS is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AZTR with price predictions
Oct 21, 2026

AZTR's Stochastic Oscillator is staying in oversold zone for 16 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

Following a +6.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZTR advanced for three days, in 116 of 144 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

AZTR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

AZTR moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AZTR crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 6 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZTR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for AZTR entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.591) is normal, around the industry mean (2.988). P/E Ratio (3.575) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (146.534) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. AZTR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for GUTS with price predictions
Oct 21, 2026

GUTS's RSI Indicator is remaining in oversold zone for 13 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where GUTS advanced for three days, in 104 of 123 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

GUTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GUTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for GUTS entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GUTS's P/B Ratio (-109.944) is very low in comparison to the industry average of (2.988). P/E Ratio (-1.264) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. GUTS's P/S Ratio (10000.000) is very high in comparison to the industry average of (438.009).

The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. GUTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GUTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

TECHNICAL ANALYSIS
Technical Analysis
AZTRGUTS
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 18 days ago
81%
Bullish Trend 8 days ago
85%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (AZTR: $0.07 vs. GUTS: $1.15)
Brand notoriety: AZTR and GUTS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AZTR: 148% vs. GUTS: 307%
Market capitalization -- AZTR: $4.33M vs. GUTS: $179.87M
AZTR [@Biotechnology] is valued at $4.33M. GUTS’s [@Biotechnology] market capitalization is $179.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AZTR’s FA Score shows that 1 FA rating(s) are green while GUTS’s FA Score has 2 green FA rating(s).

  • AZTR’s FA Score: 1 green, 4 red.
  • GUTS’s FA Score: 2 green, 3 red.
According to our system of comparison, GUTS is a better buy in the long-term than AZTR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AZTR’s TA Score shows that 4 TA indicator(s) are bullish while GUTS’s TA Score has 4 bullish TA indicator(s).

  • AZTR’s TA Score: 4 bullish, 4 bearish.
  • GUTS’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, GUTS is a better buy in the short-term than AZTR.

Price Growth

AZTR (@Biotechnology) experienced а 0.00% price change this week, while GUTS (@Biotechnology) price change was -71.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

AZTR is expected to report earnings on Nov 11, 2026.

GUTS is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
AZTR
Daily Signal:
Gain/Loss:
GUTS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

AZTR and

Correlation & Price change

A.I.dvisor indicates that over the last year, AZTR has been closely correlated with DARE. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if AZTR jumps, then DARE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AZTR
1D Price
Change %
AZTR100%
N/A
DARE - AZTR
73%
Closely correlated
-0.15%
PHIO - AZTR
34%
Loosely correlated
+0.31%
EYPT - AZTR
32%
Poorly correlated
+6.12%
GUTS - AZTR
28%
Poorly correlated
-13.53%
DYAI - AZTR
28%
Poorly correlated
+3.87%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IVOO124.220.45
+0.36%
Vanguard S&P Mid-Cap 400 ETF (IVOO)
EBUF31.200.10
+0.31%
Innovator Quarterly Trust Units (EBUF)
DEFR26.300.03
+0.11%
Aptus Deferred Income ETF
PMSE26.750.02
+0.09%
PGIM S&P 500 Max Buffer ETF - September (PMSE)
BGB11.03-0.02
-0.18%
Blackstone Strategic Credit 2027 Term Fund